



Attorney Docket No.: 122294-1058

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Yiqing Feng et al.


Serial No.: 10/695,584

Filing Date: October 27, 2003

Examiner: Unassigned

Group No.: Unassigned

For: MULTI-FUNCTIONAL HEMATOPOIETIC
FUSION PROTEINS BETWEEN
SEQUENCE REARRANGED G-CSF
RECEPTOR AGONISTS AND OTHER
HEMATOPOIETIC FACTORS


CERTIFICATE OF MAILING	
I hereby certify that this document is being deposited on this day with the U.S. Postal Service as, Express Mail under 37 C.F.R. 1.10 and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.	
	
Signature of Person Mailing Correspondence	
William Asher	
Typed or Printed Name of Person Mailing Correspondence	
Date of Signature: March 30, 2004	
EV 169246054 US	
Express Mail Label Number	

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Information Disclosure Statement

As listed on the accompanying form PTO-1449, applicants submit with this information disclosure statement copies of the indicated references, which applicants believe may be material to the examination of the above-identified application, and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made, an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. Further, the filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Written notification that the enclosed references have been considered in their entirety by return of a copy of the enclosed form, completed by the Examiner, is respectfully requested.



03-31-021

TRANSMITTAL LETTER (General - Patent Pending)	Docket No. 126181-1058
---------------------------------------------------------	---------------------------

In Re Application Of: Yiqing Feng et al.

Serial No. 10/695,584	Filing Date October 27, 2003	Examiner Unknown	Group Art Unit Unknown
--------------------------	---------------------------------	---------------------	---------------------------

Title:

MULTI-FUNCTIONAL HEMATOPOIETIC FUSION PROTEINS BETWEEN SEQUENCE REARRANGED G-CSF RECEPTOR AGONISTS AND OTHER HEMATOPOIETIC FACTORS

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Transmitted herewith is:

1. Information Disclosure Statement;
2. Form PTO-A820 (also Form PTO-1449);
3. Several cited references; and
4. Return Postcard.

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. **07-1053** as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.




Signature

Dated: **March 30, 2004**

Carol M. Nielsen Reg. No. 37,676
Gardere Wynne Sewell LLP
1000 Louisiana, Suite 3400
Houston, Texas 77002-5007
713-276-5383 phone
713-276-5555 fax
cnielsen@gardere.com

I certify that this correspondence is being deposited with the U.S. Postal Service Express Mail delivery service under 37 C.F.R. 1.10 and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Signature
William Asher

Name of Person Signing

EV 169246054 US

"Express Mail" Mailing Label Number

Date of Signature: **March 30, 2004**

CC:

**Identification Of Time Of Filing The
Information Disclosure Statement**

- ☐ This Information Disclosure Statement is being filed within three months of the filing date of the national application.
- ☐ This Information Disclosure Statement is being filed within three months of the date of entry of the national stage as set forth in § 1.491 in an international application.
- ☒ This Information Disclosure Statement is being filed before the mailing date of the First Office Action on the merits.
- ☐ This Information Disclosure Statement is being filed after three months of the filing date of the national application or after three months of the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office Action on the merits, but before the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application.

Accompanying this transmittal is:

- ☐ a statement specified in 37 CFR § 1.97(e); or
- ☐ a fee set forth in 37 CFR § 1.17(p)
- ☐ This Information Disclosure Statement is being filed after the mailing date of a final action under § 1.113, or a notice of allowance under § 1.311 but before the payment of the issue fee.

Accompanying this transmittal is:

1. a statement as specified in 37 CFR § 1.97(e); and
2. a fee set forth in 37 CFR § 1.17(p)

Statement For Information Disclosure Statement 37 CFR 1.97(E)
(Only if Required Above)

I, the person signing below, hereby state that:

- ☐ each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application

not more than three months prior to the filing of the information disclosure statement.
37 CFR § 1.97(e)(1); or

- ☐ no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in the counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 CFR § 1.97(e)(2).

Translations of Foreign Documents

This Information Disclosure Statement includes no patents that are written in Non-English languages.


Fee Payment

- ☐ attached is a check in the amount of \$ _____
- ☐ charge Deposit Account No. 07-0153
in the amount. \$ _____

A duplicate of this request is attached.

Applicants believe that no additional fees are due for the filing of this IDS. However, if any additional fees are due, or any overpayments have been made, please charge, or credit, Deposit Account No. 07-0153.

Dated: March 30, 2004




Carol M. Nielsen
Attorney for Assignee
Registration No.: 37,676
Gardere Wynne Sewell LLP
1000 Louisiana Street, Suite 3400
Houston, Texas 77002-5007
Phone: (713) 276-5383
Fax: (713) 276-6383
Email: cnielsen@gardere.com

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO. 126181-1058		SERIAL NO. 10/695,584	
				Feng et al.			
				FILING October 27, 2003		GROUP	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4,810,643	03/07/89	Souza			
		5,399,345	03/21/95	Schumacher et al.			
		4,999,291	03/12/91	Souza			
		4,877,729	10/31/89	Clark et al.			
		4,959,455	09/25/90	Clark et al.			
		5,738,849	4/14/98	Bauer et al.			
		5,677,149	10/14/97	Bauer et al.			
		5,817,487	10/6/98	Kobayashi et al.			
		5,635,599	6.3/97	Pastan et al.			
		5,567,611	10/22/96	Ralph et al.			
		5,756,083	5/26/98	Elliott et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
		WO 95/27732	10/19/95	United States			
		EP 0 783 003	10/31/96	Europe			
		EP 0 675 201	10/04/95	Europe			
		WO 92/06116	04/16/92	United States			
		WO 92/04455	03/19/92	United States			
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
		REEKE et al, "Three-Dimensional Structure of Favin: Saccharide Binding-Cyclic Permutation in Leguminous Lectins", Science, 11/28/86, Vol. 234 pp 1108-1111					
		LUGER et al, "An 8-fold Ba Barrel Protein with Redundant Folding Possibilities", Protein Engineering, Vol 3 pp 249-258					
EXAMINER				DATE CONSIDERED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 126181-1058	Application Number 10/695,584
		Applicant(s) Feng et al.	
		Filing Date October 27, 2003	Group Art Unit

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
	ZHANG et al, "Circular Permutation of T4 Lysozyme", Biochemistry, Vol 32, No. 46, 1993
	LUGER et al, "Correct Folding of Circularly Permuted Variants of a Ba Barrel Enzyme in Vivo", Science, Vol. 243
	HAHN et al, "Native-like in vivo folding of a circularly permuted jellyroll protein shown by crystal structure analysis", Proc. Natl. Acad. Sci. USA, 1994, Vol. 91, pp. 10417-10421
	LIN et al, "Rearranging the domains of pepsinogen", Protein Science, 1995, Vol. 4, pp 159-166
	YANG et al, "Aspartate transcarbamoylase containing circularly permuted catalytic polypeptide chains", Proc. Natl. Acad. Sci. USA, 1993, Vol. 90, pp. 11980-11984
	VIGNAIS et al, "Circular permutation within the coenzyme binding domain of the tetrameric glyceraldehyde-3-phosphate dehydrogenase from Bacillus stearothermophilus", Protein Science, 1995, Vol 4., pp. 994-1000
	GOLDENBERG et al, "Circular and Circularly Permuted Forms of Bovine Pancreatic Trypsin Inhibitor", J. Mol. Biol. 1983, Vol. 165, pp. 407-413
	HEMPERLY et al, "Circular permutation of amino acid sequences among legume lectins", TIBS, 1983, pp. 100-102
	KREITMAN et al, "Circularly permuted interleukin 4 retains proliferative and binding activity", Cytokine, 1995, Vol. 7, No. 4, pp. 311-318
	LI et al, "Degradation of Ornithine Decarboxylase", Mol. and Cel. Biol. 1993, Vol. 13, No. 4, pp. 2377-2383
	RITCO-VONSOVICI et al, "Is the Continuity of the Domains Required for the Correct Folding of a Two-Domain Protein?", Biochemistry, 1995, Vol. 34, pp. 16543-16551
	GARRETT et al, "Are turns required for the folding of ribonuclease T1?", Protein Science, 1996, Vol. 5., pp. 204-211

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 126181-1058	Application Number 10/695,584
		Applicant(s) Feng et al.	
		Filing Date October 27, 2003	Group Art Unit

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
	KOMAR et al, "Kinetics of translation" FEBS Letters, 1995 Vol. 376, pp. 195-198
	MACGREGOR et al, "A circularly permuted a-amylase-type", FEBS Letters, 1996, Vol. 378, pp. 263-266
	KOEBNIK et al, "Membrane Assembly of Circularly Permuted Variants", JMB, 1995, Vol. 250, pp. 617-626
	BUCHWALDER et al, "A fully active variant of Dihydrofolate Reductase with a circularly permuted sequence", Biochemistry, 1992, Vol. 31, pp. 1621-1630
	VIGUERA et al, "The order of secondary structure elements", J. Mol. Biol., 1995, Vol. 247, pp. 670-681
	MULLINS et al. "Transposition of Protein Sequences: Circular Permutation of Ribonuclease T1", J. Am. Chem. Soc., 1994, Vol. 116, pp. 5529-5533
	HORLICK et al, "Permuteins of interleukin 1B - a simplified approach for the construction of permuted proteins having new termini", Protein Engineering, USA, 1992, Vol. 5, pp.427-431
	KREITMAN et al, "A circularly permuted recombinant interleukin 4 toxin with increase activity", Proc. Natl. Acad. Sci. USA, 1993, Vol. 91, pp. 6889-3893
	WATANABE et al, "Mutant Protein of Recombinant Human Granulocyte Colony-Stimulating Factor for Receptor Binding Assay", Analytical Biochemistry, 1991, Vol. 195 pp. 38-44
	DE SAUVAGE et al, " Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand", Nature, 1994, Vol. 369, pp. 533-539
	EATON et al, Supplemental Abstract 948, Blood, Vol. 84, 1994

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.